Literature DB >> 9828813

A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies.

J A Savige1, B Paspaliaris, R Silvestrini, D Davies, T Nikoloutsopoulos, A Sturgess, J Neil, W Pollock, K Dunster, M Hendle.   

Abstract

AIM: To describe the neutrophil fluorescent patterns produced by antineutrophil cytoplasmic antibodies (ANCA) with different antigen specificities, and by other auto- and alloantibodies.
BACKGROUND: Most sera from patients with active generalised Wegener's granulomatosis result in diffusely granular cytoplasmic neutrophil fluorescence with internuclear accentuation (cANCA) and proteinase 3 (PR3) specificity. About 80% of the sera from patients with microscopic polyangiitis result in perinuclear neutrophil fluorescence with nuclear extension (pANCA) and myeloperoxidase (MPO) specificity, or a cANCA pattern with PR3 specificity. However, many different neutrophil fluorescence patterns are noted on testing for ANCA in routine immunodiagnostic laboratories.
METHODS: Sera sent for ANCA testing, or containing a variety of auto- and alloantibodies, were studied. They were examined by indirect immunofluorescence according to the recommendations of the first international ANCA workshop, and for PR3 and MPO specificity in commercial and in-house enzyme linked immunosorbent assays (ELISA).
RESULTS: Sera with typical cANCA accounted for only half of all neutrophil cytoplasmic fluorescence. Other sera had "flatter" fluorescence without internuclear accentuation, and the corresponding antigens included MPO and bactericidal/permeability increasing protein (BPI), but were usually unknown. Peripheral nuclear fluorescence without nuclear extension occurred typically when the antigens were BPI, lactoferrin, lysozyme, elastase, or cathepsin G. Most types of ANA were evident on ethanol fixed neutrophil nuclei. AntidsDNA, antiRo, and antilamin antibodies resembled pANCA. Antimicrobial and antiribosomal antibodies produced cytoplasmic fluorescence, and antiGolgi antibodies, a pANCA. Sera from patients with anti-smooth muscle antibodies were associated with cytoplasmic fluorescence. There was no neutrophil fluorescence with anti-skeletal muscle and anti-heart muscle antibodies, anti-liver/kidney microsomal, antithyroid microsomal, or antiadrenal antibodies. Alloantibodies such as antiNB1 typically resulted in cytoplasmic fluorescence of only a subpopulation of the neutrophils.
CONCLUSIONS: The ability to distinguish between different neutrophil fluorescence patterns, and the patterns seen with other auto- and alloantibodies is helpful diagnostically. However, the demonstration of MPO or PR3 specificity by ELISA will indicate that the neutrophil fluorescence is probably clinically significant, and that the diagnosis is likely to be Wegener's granulomatosis or microscopic polyangiitis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828813      PMCID: PMC500847          DOI: 10.1136/jcp.51.8.568

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  30 in total

1.  Delineation of a standard procedure for indirect immunofluorescence detection of ANCA.

Authors:  A Wiik
Journal:  APMIS Suppl       Date:  1989

Review 2.  Serial ANCA testing is useful in monitoring disease activity of patients with ANCA-associated vasculitides.

Authors:  J W Tervaert; C A Stegeman; C G Kallenberg
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  1996-10       Impact factor: 0.670

3.  Circulating anti-elastase in systemic lupus erythematosus.

Authors:  L Nässberger; H Jonsson; A G Sjöholm; G Sturfelt; A Heubner
Journal:  Lancet       Date:  1989-03-04       Impact factor: 79.321

4.  Anti-neutrophil nuclear antibody in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis.

Authors:  J A Snook; R W Chapman; K Fleming; D P Jewell
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

5.  Leucocyte-specific anti-nuclear factors in patients with felty's syndrome, rheumatoid arthritis, systemic lupus erythematosus and other diseases.

Authors:  V Faber; P Elling
Journal:  Acta Med Scand       Date:  1966-03

Review 6.  Granulocyte-specific antinuclear antibodies. Possible significance for the pathogenesis, clinical features and diagnosis of rheumatoid arthritis.

Authors:  A Wiik
Journal:  Allergy       Date:  1980-06       Impact factor: 13.146

7.  Granulocyte specific antinuclear antibodies in ulcerative colitis. Aid in differential diagnosis of inflammatory bowel disease.

Authors:  H Nielsen; A Wiik; J Elmgreen
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1983-02

8.  Reactivity of anti-neutrophil cytoplasmic autoantibodies with HL-60 cells.

Authors:  L A Charles; R J Falk; J C Jennette
Journal:  Clin Immunol Immunopathol       Date:  1989-11

9.  Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.

Authors:  F J van der Woude; N Rasmussen; S Lobatto; A Wiik; H Permin; L A van Es; M van der Giessen; G K van der Hem; T H The
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

10.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.

Authors:  R J Falk; J C Jennette
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

View more
  18 in total

1.  Pitfalls of formalin fixation for determination of antineutrophil cytoplasmic antibodies.

Authors:  S M Chowdhury; V Broomhead; G P Spickett; R Wilkinson
Journal:  J Clin Pathol       Date:  1999-06       Impact factor: 3.411

2.  How to test for antineutrophil cytoplasmic antibodies--evidence based immunology?

Authors:  G P Spickett; V Broomhead
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

3.  Immunofluorescent patterns associated with ANCA.

Authors:  R J Lock; D J Unsworth
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

Review 4.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

5.  Photodynamic treatment of pooled coumarin plasma for external quality assessment of the prothrombin time.

Authors:  A M van den Besselaar; A C Moor
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

6.  Apolipoprotein H, a new mediator in the inflammatory changes ensuring in jeopardised human myocardium.

Authors:  H W Niessen; W K Lagrand; H J Rensink; C J Meijer; L Aarden; C E Hack; C Visser
Journal:  J Clin Pathol       Date:  2000-11       Impact factor: 3.411

Review 7.  Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them?

Authors:  C Beauvillain; Y Delneste; G Renier; P Jeannin; J F Subra; A Chevailler
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

8.  Evaluation of the combined application of ethanol-fixed and formaldehyde-fixed neutrophil substrates for identifying atypical perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease.

Authors:  Maria Papp; Istvan Altorjay; Gabriella Lakos; Judit Tumpek; Sandor Sipka; Tamas Dinya; Karoly Palatka; Gabor Veres; Miklos Udvardy; Peter Laszlo Lakatos
Journal:  Clin Vaccine Immunol       Date:  2009-02-04

9.  Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis.

Authors:  Govind K Makharia; Vikas Sachdev; Rajiva Gupta; Suman Lal; R M Pandey
Journal:  Dig Dis Sci       Date:  2006-12-08       Impact factor: 3.487

Review 10.  New platform technology for comprehensive serological diagnostics of autoimmune diseases.

Authors:  Annika Willitzki; Rico Hiemann; Vanessa Peters; Ulrich Sack; Peter Schierack; Stefan Rödiger; Ursula Anderer; Karsten Conrad; Dimitrios P Bogdanos; Dirk Reinhold; Dirk Roggenbuck
Journal:  Clin Dev Immunol       Date:  2012-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.